A
Adriana C. Gamboa
Researcher at Emory University
Publications - 51
Citations - 608
Adriana C. Gamboa is an academic researcher from Emory University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 8, co-authored 44 publications receiving 212 citations. Previous affiliations of Adriana C. Gamboa include University of Minnesota.
Papers
More filters
Journal ArticleDOI
Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine.
TL;DR: The latest evidence guiding the histiotype‐specific management of extremity/truncal and retroperitoneal STS with regard to surgery, radiation, and chemotherapy is summarized.
Journal ArticleDOI
A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients
Mohammad Y. Zaidi,Alexandra G. Lopez-Aguiar,Jeffrey M. Switchenko,Joseph Lipscomb,Valentina Andreasi,Stefano Partelli,Adriana C. Gamboa,Rachel M. Lee,George A. Poultsides,Mary Dillhoff,Flavio G. Rocha,Kamran Idrees,Clifford S. Cho,Sharon M. Weber,Ryan C. Fields,Charles A. Staley,Massimo Falconi,Shishir K. Maithel +17 more
TL;DR: This international, novel, internally validated RRS accurately stratifies recurrence-free survival for patients with resected PanNETs and recommends surveillance intervals of 12, 6, and 3 months for low, intermediate, and high RRS patients, respectively to minimize radiation exposure and optimize cost/resource utilization.
Journal ArticleDOI
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer.
TL;DR: The natural history of gastric cancer, currently available neoadjuvant and adjuvant therapies for resectable disease, and existing evidence supporting various approaches to CRS and intraperitoneal chemotherapy are outlined.
Journal ArticleDOI
The Landmark Series: Gallbladder Cancer
TL;DR: In this article, a review summarizes available trials and highlights the best available evidence that form the basis of consensus statements for the multimodal management of gallbladder carcinoma. But there is no level I evidence to guide neoadjuvant therapy or surgical management, current consensus is based on strong retrospective data.
Journal ArticleDOI
Optimal timing and treatment strategy for pancreatic cancer
Adriana C. Gamboa,Manali Rupji,Jeffrey M. Switchenko,Rachel M. Lee,Michael K. Turgeon,Benjamin I. Meyer,Maria C. Russell,Kenneth Cardona,David A. Kooby,Shishir K. Maithel,Mihir M. Shah +10 more
TL;DR: For pancreatic adenocarcinoma (PDAC), no studies have established any association between earlier treatment initiation and long‐term outcomes and an optimal type of initial treatment for the localized disease remains ill‐defined.